MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
Old Articles: <Older 6161-6170 Newer>
The Motley Fool
January 28, 2010
Brian Orelli
Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say? mark for My Articles 524 similar articles
The Motley Fool
January 28, 2010
Brian Orelli
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. mark for My Articles 460 similar articles
The Motley Fool
January 28, 2010
Brian Orelli
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. mark for My Articles 997 similar articles
The Motley Fool
January 28, 2010
Brian Orelli
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. mark for My Articles 448 similar articles
The Motley Fool
January 28, 2010
Brian Orelli
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. mark for My Articles 1664 similar articles
The Motley Fool
January 27, 2010
Brian Orelli
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that. mark for My Articles 321 similar articles
The Motley Fool
January 27, 2010
Brian Orelli
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note. mark for My Articles 248 similar articles
The Motley Fool
January 27, 2010
Brian Orelli
The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs. mark for My Articles 161 similar articles
The Motley Fool
January 26, 2010
Brian Orelli
Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010. mark for My Articles 259 similar articles
The Motley Fool
January 26, 2010
Brian Orelli
Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug. mark for My Articles 169 similar articles
<Older 6161-6170 Newer>    Return to current articles.